InvestorsHub Logo
Followers 4
Posts 726
Boards Moderated 0
Alias Born 01/13/2014

Re: microgecko post# 337

Thursday, 08/27/2015 5:43:45 PM

Thursday, August 27, 2015 5:43:45 PM

Post# of 1086
From a specialty biotech analyst...
OncoGeneX (NASDAQ: OGXI) is another company with near-term catalysts that's declined with the market. The company has made excellent progress in working with the FDA for its lead cancer drug, custirsen. The FDA has accepted a change in the clinical trial that allows the company to use data in patients with a poor prostate cancer prognosis. Data from that trial are expected by the end of the year, followed by data for a lung cancer trial in the second half of next year. It is a buy up to $2.50.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACHV News